Russia is set to register its second coronavirus vaccine on October 15, the vaccine developer said on Friday, according to a Reuters report. Developed by Vector’s State Research Center for Virology and Biotechnology, the experimental vaccine has recently completed its early-stage human trials.
“The Ministry of Health of the Russian Federation <...> started the registration procedure for the EpiVacCorona vaccine. <...> The completion of the EpiVacCorona vaccine registration procedure is scheduled for October 15, 2020, “the press service of the Federal Surveillance Service for the Protection of Consumer Rights and Human Well-being previously reported.
The Vector Research Center obtained permission from the Russian Ministry of Health to conduct clinical trials of its vaccine on volunteers in July. The first volunteer was injected with the vaccine on July 27. The final group of 20 volunteers was discharged from the medical center on September 8, according to TASS report.
“The clinical trials have been very successful. The volunteers are developing the necessary titers and no one has any clinical signs after the vaccine, no temperature or any other reaction,” said Anna Popova, Russia’s chief medical officer.
The drugmaker will begin phase III trials in November-December. About 30,000 volunteers will participate in post-registration trials of the coronavirus vaccine, the press service of the Federal Surveillance Service for the Protection of Consumer Rights and Human Welfare said. TASS. The vaccine will be manufactured at the Vector Research Center industrial site.
“After the registration of the vaccine, the centers to carry out the post-registration trials will be selected, in which 30,000 volunteers will participate,” the statement read.
“Following the registration of the EpiVacCorona vaccine in October 2020, clinical trials involving volunteers from the age group over 60 and people with chronic diseases, as well as post-registration, placebo-controlled clinical trials involving 5,000 participants are planned. adult volunteers of different age groups, “explained the press service of the health regulator, according to TASS.
“There are not many vaccines of this type in the world, which are being developed by the Vector Center. This is quite a complicated process,” Popova said. TASS.
Russia had approved a COVID-19 vaccine, called Sputnik V, in August even before its final test. The vaccine is currently undergoing final trials in Russia on around 40,000 subjects. Sputnik V has been developed by the Gamaleya National Research Center for Epidemiology and Microbiology and RDIF.
Indian pharmaceutical company Dr Reddy’s has collaborated with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of the Sputnik V vaccine as well as its distribution.
.
